Intellia Therapeutics, Inc.
NTLA
Rank in Stocks
#6534
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing... Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
Share Price
$12.11
Last synced: 2026-11-09
Market Cap
$1.70B
Change (1 day)
6.70%
Change (1 year)
39.68%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Intellia Therapeutics, Inc. (NTLA)
Category
Healthcare
EPS for Intellia Therapeutics, Inc. (NTLA)
EPS as of September 2026 TTM: $-3.35
According to Intellia Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-3.35. At the end of 2025 the company had an EPS of $-3.81, an increase over its 2024 EPS of $-5.25.
EPS history for Intellia Therapeutics, Inc. from 2014 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-3.35 | -12.07% |
| 2025 | $-3.81 | -27.43% |
| 2024 | $-5.25 | -3.14% |
| 2023 | $-5.42 | -12.01% |
| 2022 | $-6.16 | 62.96% |
| 2021 | $-3.78 | 57.50% |
| 2020 | $-2.40 | 22.45% |
| 2019 | $-1.96 | -1.01% |
| 2018 | $-1.98 | 5.32% |
| 2017 | $-1.88 | 106.59% |
| 2016 | $-0.91 | 30.00% |
| 2015 | $-0.70 | -49.64% |
| 2014 | $-1.39 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -567.46% |
US
|
|
| $-7.07 | 111.04% |
US
|
|
| $-5.29 | 57.91% |
AU
|
|
| $12.88 | -484.48% |
BE
|
|
| $21.56 | -743.58% |
NL
|
Questions about Intellia Therapeutics, Inc.'s earnings per share (EPS)
What is Intellia Therapeutics, Inc.'s earnings per share (EPS)?
Intellia Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-3.35, as of Sep 2026.
What was Intellia Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Intellia Therapeutics, Inc.'s earnings per share (EPS) was $-3.81, compared with $-5.25 in 2024.
How has Intellia Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Intellia Therapeutics, Inc.'s earnings per share (EPS) was highest in 2020 ($-2.40) and lowest in 2022 ($-6.16).
How does Intellia Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Intellia Therapeutics, Inc.'s earnings per share (EPS) ($-3.35) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.